Pillai Rathi N,Fennell Dean A,Kovcin Vladimir N,Ciuleanu Tudor E,Ramlau Rodryg,Kowalski Dariusz,Schenker Michael,Yalcin Ilker,Teofilovici Florentina,Vukovic Vojo M,Ramalingam Suresh S (2020) Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non?Small-Cell Lung Cancer (GALAXY-2), JOURNAL OF CLINICAL ONCOLOGY, vol. 38, br. 6, str. 613-+ (Article) 

Pillai Rathi N,Fennell Dean,Kovcin Vladimir N,Ciuleanu Tudor E,Ramlau Rodryg,Kowalski Dariusz,Schenker Michael,Perin Branislav M,Yalcin Ilker,Teofilovici Florentina,Vukovic Vojo M,Ramalingam Suresh S (2017) Phase 3 Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, with Docetaxel versus Docetaxel in Advanced Non-Small Cell Lung Cancer (GALAXY-2), JOURNAL OF THORACIC ONCOLOGY, vol. 12, br. 1, str. S7-S8 (Meeting Abstract) 

Ramalingam Suresh S,...,Zaric Bojan,Andric Zoran G,...,(broj koautora 22) (2015) A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1), ANNALS OF ONCOLOGY, vol. 26, br. 8, str. 1741-1748 (Article) 

Ramalingam Suresh S,Zaric Bojan,Ceric Timur,...,Samarzija Miroslav,...,Vukovic Vojislav M,(broj koautora 20) (2014) Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib itt combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma., JOURNAL OF CLINICAL ONCOLOGY, vol. 32, br. 15, str. - (Meeting Abstract) 

Ramalingam Suresh S,...,Zaric Bojan,...,Andric Zoran G,...,(broj koautora 26) (2013) Galaxy-1: Randomized Phase Ii Study of Docetaxel with Or Without Ganetespib in Advanced Lung Adenocarcinoma: Results in Biomarker Sub-Groups and All Adenocarcinoma Patients., JOURNAL OF THORACIC ONCOLOGY, vol. 8, br. , str. S139-S139 (Meeting Abstract) 

Ramalingam Suresh S,...,Andric Zoran G,...,Zaric Bojan,...,Vukovic Vojislav M,...,(broj koautora 20) (2013) A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1)., JOURNAL OF CLINICAL ONCOLOGY, vol. 31, br. 18, str. - (Meeting Abstract) 

Ramalingam Suresh S,...,Andric Zoran G,...,Zaric Bojan,Ceric Timur,...,Vukovic Vojislav M,...,(broj koautora 20) (2013) A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1), JOURNAL OF CLINICAL ONCOLOGY, vol. 31, br. 15, str. - (Meeting Abstract) 

Fennell DA,Goss GD,Andric Zoran G,Bondarenko Igor N,Zaric Bojan,Ceric Timur,Poddubskaya Elena,Teofilovici F,Guo W,Ramalingam Suresh S (2013) Ganetespib in combination with docetaxel versus docetaxel alone in second line adenocarcinoma patients with KRAS mutations and elevated LDH levels, EUROPEAN JOURNAL OF CANCER, vol. 49, br. , str. S801-S801 (Meeting Abstract)